Trxade Health Inc. (NASDAQ: MEDS) has been on a mission to digitalize the retail pharmacy experience by providing a platform for independent pharmacies to operate efficiently. While expanding its customer network constantly, the online drug procurement marketplace has been focused on expanding the core business and pursuing strategic partnerships.
The digital platform helps optimize drug procurement and patient engagement through the compnay’s business segments of Trxade.com, Community Specialty Pharmacy, and Trxade Prime. Speaking to AlphaStreet, after reporting impressive results for the second quarter, Trxade’s chief executive officer Suren Ajjarapu provided updates on the company’s operations and growth strategy.
Suren attributed the sharp increase in second-quarter revenues mainly to the strong performance of the Integra Pharma subsidiary — doing business as Trxade Prime — and refocusing on the core business. “…our refocus to core business and Trxade Prime, and also we have added new members vs the Q1 2021,” he said.
Of late, Trxade Prime has been growing at a steady pace, increasing its contribution to the top line. Reflecting the uptrend, combined with strong momentum at the core Trxade segment, revenues rose sharply in the most recent quarter.
Recently, Trxade Prime inked a distribution partnership with GALT Pharmaceuticals to help independent pharmacies and members access top medication products more effectively. According to Suren, a clear picture of the partnership’s effect on the business would emerge in the coming quarters. He said, “this is a new partnership, we are understanding the nuance of this, so we will be able to give more color in the coming quarters.”
One of the highlights of the second-quarter report was a 33% fall in operating expenses, thanks to the management’s initiatives to reduce costs that contributed significantly to the bottom-line improvement. The CEO said the company has cut down on some of the staff and is working on less spending on the new technology initiatives.
On being asked about the growth plan, he said the strategy is to be “more focused on the core platform and Trxade Prime and building relationships with POS Systems.” Going forward, the management is likely to continue looking for suitable deals and partnerships — it had signed a joint venture agreement with Exchange Health early this year to form pharmaceutical platform SOSRx to provide drugmakers a single platform to optimize the sale and distribution of their inventory.
READ management/analysts’ comments on Trxade’s Q2 2022 results
In the quarter ended June 2022, for which the results were published recently, revenues of the core Trxade business and the Integra Pharma segment grew 12% and 89% respectively, offsetting a 32% contraction in the Community Specialty Pharmacy division. Total revenues climbed 73% annually to $3.28 million. As a result, net loss narrowed sharply to $1.08 million or $0.13 per share from $2.58 million or $0.32 per share in the corresponding period of last year. The company added 319 new registered members during the three-month period.
Trxade generates revenue by charging an administrative fee of up to 6% of the buying prices of generic pharmaceutical products and collecting up to1% on brand pharmaceuticals that pass through the platform. It had 13,815+ registered members on the platform at the end of June, which includes 685 new members who were added in the first six months of the year. n
In the past three months, shares of the company mostly moved sideways and stayed below the $2-mark. The stock traded slightly lower in the early hours of Tuesday’s session.
Image and article originally from news.alphastreet.com. Read the original article here.